Tregitope289

Send Inquiry
Tregitope289
Details
Regulatory T-cell epitope Tregitope 289;
Category: Immunomodulatory epitope / Treg-activating peptide.
Peptide Purity (HPLC) ≥95%
Structure Linear regulatory epitope (Tregitope 289)
Solubility Water, DMSO cosolvent, PBS
Storage Powder, −20°C, dry, light-protected
Category
Epitope Peptides
Share to
Description

Shanghai Sonyt Biotechnology Co., Ltd. is one of the leading manufacturers and suppliers of tregitope289 in China, also supports custom service. Welcome to wholesale bulk high quality tregitope289 from our factory. Contact us for more details.

 

Description A synthetic IgG-derived regulatory epitope inducing/expanding antigen-specific Tregs; used for the negative regulation of autoimmunity, allergy and transplant tolerance.

 

Product Basic Information Table

 

Product Standard English Name Product Abbreviation / Alias Function Tags (comma-separated) Core Structure Molecular Formula Exact Mass (Da) Average MW (Da) Salt Form Length (aa)
Tregitope 289 (human IgG Fc-derived natural regulatory T cell epitope; H-EEQYNSTYRVVSVLTVLHQDW-NH2, C-terminal amide) Treg289; Tregitope 289-amide; IgG Fc Treg epitope 289 Treg epitope,IgG Fc,MHC-II,regulatory T cell,immune tolerance,autoimmunity,transplant tolerance,IVIG mechanism,immunogenicity,biologics,nTreg expansion,anti-inflammatory Full sequence H-E-E-Q-Y-N-S-T-Y-R-V-V-S-V-L-T-V-L-H-Q-D-W-NH2; one-letter EEQYNSTYRVVSVLTVLHQDW; length 21 aa; free N-terminus; C-terminal amide (-NH2); derived from human IgG1 heavy-chain Fc (CH2-CH3 boundary, approx. EU residues 294-314); sensitive residues: 2 Tyr and 1 Trp (protect from light); no free Cys, no Met. C115H173N31O36 2564.27 2565.82 TFA salt (per SB-Peptide datasheet: Counter-Ion = TFA Salts) 21

 

Physicochemical Solubility & Storage Parameters

 

Product Code Appearance Long-term Storage Short-term Storage Solution Stability Solid Powder Stability
PEP-TREG289-01 White to off-white powder (TFA salt) Store at -20°C or below, protected from light and moisture; preferably under inert gas; keep sealed. Short-term storage/transport at 2-8°C (up to a few weeks), protected from light and moisture. Moderately hydrophilic but somewhat hydrophobic (multiple Val/Leu); first dissolve in a small volume of DMSO, then dilute with sterile water or PBS to working concentration; protect from light due to Trp/Tyr; prepare fresh and avoid repeated freeze-thaw. Stable as powder; keep sealed and dry; long-term protect from light (Trp/Tyr); avoid repeated freeze-thaw.

 

Functional Description

 

Product Code Frontend Short Summary Detailed Biological Function Description Applicable Research Areas (comma-separated) Targets / Receptors
PEP-TREG289-01 Tregitope 289 is a natural MHC-II-binding regulatory T cell epitope derived from the Fc region of human IgG (named by De Groot et al., 2008). It is a 21-mer C-terminally amidated peptide, sequence EEQYNSTYRVVSVLTVLHQDW, formula C115H173N31O36, exact mass ~2564.27 Da, TFA salt. Presented on MHC-II and recognized by the TCR, it selectively activates and expands natural regulatory T cells (nTregs) and is used in autoimmunity, transplant tolerance, IVIG mechanism and biologic immunogenicity studies. Tregitope 289 is one of the two classic natural MHC-II-binding Treg epitopes (along with Tregitope 167) identified by De Groot et al. (2008) within the IgG Fc region. Mechanistically, professional antigen-presenting cells (e.g., dendritic cells) take up IgG or Tregitope-containing fusion proteins, process the peptide and present it on MHC-II (HLA-DR/DQ); cognate CD4+CD25+Foxp3+ natural regulatory T cells (nTregs) recognize it via their TCR and become activated, undergoing antigen-specific expansion and secreting suppressive cytokines such as TGF-beta and IL-10, which mediate bystander suppression of effector Th1/Th17 responses. This pathway is considered a key basis for the anti-inflammatory and therapeutic effects of intravenous immunoglobulin (IVIG). Applications include: (1) antigen-specific tolerance induction in autoimmune models (EAE/MS, type 1 diabetes, arthritis); (2) tolerance induction in organ/cell transplantation; (3) fusion of Tregitope 289 with autoantigen peptides (e.g., insulin) as albumin-fusion tolerogens; (4) assessment of therapeutic-antibody/biologic immunogenicity and anti-drug antibody (ADA) risk; and (5) studies of fetomaternal tolerance, allergy and inflammation. The C-terminal amide enhances stability and protease resistance. autoimmunity,organ transplantation,immune tolerance,multiple sclerosis,type 1 diabetes,rheumatoid arthritis,IVIG mechanism,biologic immunogenicity,vaccine design,anti-inflammatory,fetomaternal tolerance,allergy MHC-II (HLA-DR/DQ); TCR; CD4+CD25+Foxp3+ nTreg

 

 

 

 

Hot Tags: tregitope289, China tregitope289 manufacturers, suppliers, factory, cateninpeptide, 124454-83-7, 125366-42-9, 265669-37-2, CEF4, epitope peptides

Send Inquiry